Comparative Pharmacology
Head-to-head clinical analysis: RELEUKO versus ZARXIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RELEUKO versus ZARXIO.
RELEUKO vs ZARXIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to specific cell surface receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
5 mcg/kg subcutaneously once daily. Round to nearest vial size (300 mcg/0.5 mL or 480 mcg/0.8 mL).
None Documented
None Documented
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
Terminal elimination half-life is approximately 3.5-4.5 hours in healthy adults; prolonged in renal impairment (up to 40 hours in end-stage renal disease).
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Primarily renal (70-80% as unchanged drug) via glomerular filtration; biliary/fecal excretion is negligible (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor